8-K: Evoke Pharma Acquired by QOL Medical for $11/Share

Sentiment:

Merger Announcement 4 November 2025 7:12 AM

Evoke Pharma has entered into a definitive agreement to be acquired by QOL Medical for $11.00 per share in cash, representing a 139.7% premium.

Better than expectedThe acquisition price of $11.00 per share represents a significant premium of 139.7% over Evoke's closing share price on November 3, 2025, offering substantial immediate value to shareholders.

Summary

Evoke Pharma, Inc. has agreed to be acquired by QOL Medical, LLC through a tender offer and subsequent merger.
QOL Medical's subsidiary, QOL-EOS Merger Sub, Inc., will launch a tender offer to acquire all outstanding shares of Evoke for $11.00 in cash per share.
The acquisition price represents a 139.7% premium over Evoke's closing share price on November 3, 2025.
Evoke's Board of Directors unanimously approved the merger agreement and recommended that stockholders tender their shares.
The transaction is expected to close by the end of 2025 and is not subject to a financing condition, with QOL Medical planning to use cash on hand.
Upon completion, Evoke Pharma will become a wholly-owned subsidiary of QOL Medical and will cease to be a publicly traded company.
Certain directors, key employees, and stockholders, representing approximately 10.4% of outstanding shares, have entered into support agreements to tender their shares and exercise/surrender warrants.

Sentiment

Score: 9

Explanation: The sentiment is highly positive due to the significant 139.7% premium offered to shareholders in an all-cash transaction, indicating a strong valuation and immediate return for investors. The unanimous board approval and the acquirer's commitment to GIMOTI's continuity further bolster positive sentiment.

Positives

The acquisition offers a substantial premium of 139.7% to Evoke's recent closing share price, providing significant immediate value to shareholders.
The transaction is an all-cash offer, eliminating market volatility and providing certainty of value for tendering shareholders.
QOL Medical brings strong commercial gastrointestinal (GI) experience and manufacturing capabilities, which is expected to ensure the continued commercial availability and support for GIMOTI.
The acquisition is not subject to a financing condition, indicating a high likelihood of completion.

Negatives

Evoke Pharma will cease to be a publicly traded company, removing future growth potential for existing shareholders.
The transaction may cause disruption to relationships with employees, collaborators, vendors, and other business partners during the transition period.
Management's attention may be diverted from ongoing business operations due to the transaction.

Risks

Uncertainties exist regarding the timing and completion of the tender offer and the merger.
There are uncertainties about the percentage of Evoke stockholders who will tender their shares in the offer.
The possibility of competing offers being made could complicate or delay the transaction.
Various closing conditions for the tender offer or the merger may not be satisfied or waived.
Disruption caused by the transaction could make it more difficult to maintain relationships with employees, collaborators, vendors, and other business partners.
There is a risk that stockholder litigation in connection with the transactions may result in significant costs of defense, indemnification, and liability.
Potential changes in QOL Medical's strategic vision post-acquisition could impact GIMOTI's future development or commercialization.

Future Outlook

The transaction is expected to ensure the continued commercial availability of GIMOTI and the continuation of Evoke's partnership with Eversana. QOL Medical aims to strengthen its GI portfolio and expand its reach in specialty gastrointestinal care, building on its existing infrastructure.

Management Comments

Matt D'Onofrio, Founder and CEO of Evoke, stated that the transaction recognizes the importance of what they've built, a differentiated, patient-centered therapy with a growing commercial presence, and that QOL Medical is an ideal partner due to their strong commercial GI experience, manufacturing capabilities, and commitment to continuity.
Derick Cooper, CEO of QOL Medical, expressed excitement about the strategic alignment, noting that Evoke's innovative therapy addresses a significant unmet need in GI care and offers meaningful clinical benefits for patients. He added that GIMOTI strengthens QOL Medical's GI portfolio and advances their mission to support patients with rare and underserved GI conditions, allowing them to build on existing infrastructure and expand reach.

Industry Context

This acquisition highlights the ongoing consolidation and strategic alignment within the biopharmaceutical industry, particularly in niche markets like gastrointestinal and rare diseases. QOL Medical's focus on acquiring and commercializing orphan and GI products aligns with a trend of companies seeking to strengthen specialized portfolios. GIMOTI's unique position as the only FDA-approved nasal spray for diabetic gastroparesis makes it a valuable asset in an underserved therapeutic area, attracting strategic buyers looking for differentiated products.

Management Changes

Role	Previous Person	New Person	Effective Date	Reason
Chief Executive Officer	Matthew J. D'Onofrio	N/A (employment terminated)	Immediately following the Effective Time of the Merger	Termination of employment as part of the acquisition, followed by a transition services agreement.
Chief Financial Officer	Mark Kowieski, CPA	N/A (employment terminated)	Immediately following the Effective Time of the Merger	Termination of employment as part of the acquisition, followed by a transition services agreement.
Chief Medical Officer	Marilyn R. Carlson, M.D.	N/A (employment terminated)	Immediately following the Effective Time of the Merger	Termination of employment as part of the acquisition, followed by a transition services agreement.
Board of Directors	Current Evoke Pharma Directors	Directors of QOL-EOS Merger Sub, Inc. or other Parent designees	Effective Time of the Merger	Change in control due to the merger.
Officers	Current Evoke Pharma Officers	Current Evoke Pharma Officers or other Parent designees	Effective Time of the Merger	Change in control due to the merger, with potential for current officers to continue or new designees.

Corporate Governance

Change Type	Description	Effective Date	Impact Assessment
Bylaws and Certificate of Incorporation	The certificate of incorporation and bylaws of Evoke Pharma will be amended and restated to reflect the Surviving Corporation's structure as a subsidiary of QOL Medical.	Effective Time of the Merger	Aligns corporate governance with QOL Medical's ownership and operational structure.
Employee Stock Purchase Plan (ESPP) Termination	The Company's 2013 Employee Stock Purchase Plan will be terminated, with no new offering periods and existing contributions used to purchase shares prior to the merger.	Effective Time of the Merger	Eliminates future equity purchase opportunities for employees under the ESPP.
401(k) Plan Termination	The Company's 401(k) Plan will be terminated, with all accounts becoming 100% vested and distributed to participants.	Immediately prior to the Effective Time of the Merger	Ensures full vesting and distribution of retirement savings for employees.
Non-Employee Director Compensation Policy Termination	The Evoke Pharma, Inc. Non-Employee Director Compensation Policy will be terminated, with outstanding payments/equity awards paid and no further compensation post-merger.	Immediately prior to the Effective Time of the Merger	Streamlines director compensation in anticipation of the company becoming a private subsidiary.

Legal Proceedings

Risk of stockholder litigation in connection with the transactions contemplated by the Merger Agreement, which may result in significant costs of defense, indemnification, and liability.

Related Party Transactions

Parent and Merger Sub entered into tender and support agreements with certain directors and key employees of Evoke, and certain stockholders and warrant holders, who collectively hold approximately 10.4% of outstanding shares. These parties agreed to tender their shares and exercise/surrender warrants.

Stakeholder Impact

Shareholders: Will receive a significant cash premium of 139.7% for their shares, providing immediate and certain value.
Employees: Key executives will have their employment terminated but will receive severance benefits and enter into transition services agreements. All outstanding company options will accelerate and convert to cash. The 401(k) plan will be terminated with full vesting and distribution.
Customers/Patients: The continued commercial availability of GIMOTI is expected, with QOL Medical committed to supporting patients with GI and rare diseases.
Eversana (Commercial Partner): The existing Commercial Services Agreement and Loan Agreement will be clarified and potentially terminated or continued under new terms, including specific payments for deferred costs and loan amounts.

Next Steps

QOL Medical, through its subsidiary, will initiate a tender offer to acquire all outstanding shares of Evoke Pharma.
Evoke Pharma will file a Solicitation/Recommendation Statement on Schedule 14D-9 with the SEC.
Upon successful completion of the tender offer, QOL-EOS Merger Sub, Inc. will merge into Evoke Pharma.
Evoke Pharma shares will be delisted from NASDAQ and deregistered with the SEC after the Effective Time.

Key Dates

Date	Description
2020-01-21	Original Commercial Services Agreement (CSA) and Loan Agreement between Evoke and Eversana.
2022-02-01	Amendment No. 1 to the Commercial Services Agreement between Evoke and Eversana.
2022-11-03	Amendment No. 2 to the Master Services Agreement between Evoke and Eversana.
2023-01-01	Start date for compliance and financial reporting period referenced in the filing.
2024-12-31	End of fiscal year for which the Company's management completed an assessment of internal control over financial reporting.
2025-04-07	Date of Mutual Confidentiality Agreement between Parent and the Company.
2025-09-30	Reference date for Eversana Cumulative Deferred Costs and Commercialization Costs.
2025-10-29	Date of Eversana Letter Agreement clarifying the Commercial Services Agreement.
2025-10-30	Capitalization Date for outstanding Company Shares, Options, and Warrants.
2025-11-03	Date of Agreement and Plan of Merger, Tender and Support Agreements, Amended and Restated Employment Agreements, and Transition Services Agreements.
2025-11-03	Evoke's closing share price reference date for premium calculation.
2025-11-04	Date of joint press release regarding the merger agreement.
2025-12-31	Expected closing date for the transaction.
2026-01-31	Latest payment date for 2025 annual bonus for executives if Involuntary Termination occurs prior to payment and within 24 months of a Change of Control.
2026-05-03	Termination Date for the Merger Agreement if the Offer has not been consummated.
2026-12-31	Natural expiration date of the Eversana Commercial Services Agreement.

Recommendation

strong buy

For existing shareholders, the recommendation is a strong buy to tender shares into the offer. The proposed acquisition price of $11.00 per share represents a substantial 139.7% premium over the recent closing price, offering a significant and immediate cash return. The unanimous board approval and the all-cash nature of the deal, without a financing condition, indicate a high probability of successful completion, making it a compelling opportunity for shareholders to realize substantial value.

Keywords

Evoke Pharma, QOL Medical, Merger Agreement, Tender Offer, Acquisition, GIMOTI, Diabetic Gastroparesis, Biopharmaceutical, Specialty Pharma, Cash Offer, Premium

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.